AccessibilityHelp

Most Active Stocks Daily Stock Gainers Daily Stock Losers

Most Active Stocks Daily Stock Gainers Daily Stock Losers

Brian Orelli, PhD

TMFBiologyFool

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Articles by Brian Orelli, PhD — Page 4

Drugmakers_Are_Vying_for_a_Multi-Billion-Dollar_Market[1]

Apr 14, 2021 by Brian Orelli, PhD and Keith Speights

Drugmakers Are Vying for a Multibillion-Dollar Market

Too bad there are issues with side effects.

Is_Bluebird_Bio_a_Bad_News_Buy[1]

Apr 14, 2021 by Brian Orelli, PhD and Keith Speights

Is bluebird bio a Bad News Buy?

The biotech has had a rough couple of years.

Here_s_A_Multi-Billion_Dollar_Market_for_Johnson_&_Johnson[1]

Apr 13, 2021 by Brian Orelli, PhD and Keith Speights

Here's a Multibillion-Dollar Market for Johnson & Johnson

However, the healthcare conglomerate might be too late to find a niche in multiple sclerosis.

Will_Amazon_Move_Into_the_Telehealth_Space[1]

Apr 13, 2021 by Brian Orelli, PhD and Keith Speights

Will Amazon Move Into the Telehealth Space?

Amazon Care is rolling out to employees. Could customers be next?

A_Short_Delay_Is_Still_Bad_News_for_AbbVie[1]

Apr 13, 2021 by Brian Orelli, PhD and Keith Speights

A Short Delay Is Still Bad News for AbbVie

Rinvoq's FDA approval decision could be a sign the drug class is under investigation.

Doctor Patient Report

Apr 9, 2021 by Brian Orelli, PhD

Here's Why Shares of Affimed Skyrocketed Today

A 100% response rate is impressive, albeit in just four patients.

Are_Bluebird_Bio_s_Troubles_Behind_It[1]

Apr 2, 2021 by Brian Orelli, PhD and Keith Speights

Are bluebird bio's Troubles Behind It?

The company offers more evidence that its gene therapy isn't causing cancer.

Pfizer_and_BioNTech_s_Vaccine_Performs_Well_in_the_Real_World[1]

Apr 2, 2021 by Brian Orelli, PhD and Keith Speights

Pfizer and BioNTech's Vaccine Performs Well in the Real World

Clinical trial data is good. Real-world data is great.

Novavax_s_Vaccine_Data_Keeps_Getting_Better[1]

Apr 1, 2021 by Brian Orelli, PhD and Keith Speights

Novavax's Vaccine Data Keeps Getting Better

The vaccine appears to protect against the new variants.

Can_Ocular_Therapeutix_Reach_Its_Full_Potential[1]

Apr 1, 2021 by Brian Orelli, PhD and Keith Speights

Can Ocular Therapeutix Reach Its Full Potential?

The biotech has a ways to go.

Are_Ultra-High_Drug_Prices_Sustainable[1]

Apr 1, 2021 by Brian Orelli, PhD and Keith Speights

Are Ultra-High Drug Prices Sustainable?

It depends on the ultimate cost to insurers.

Vaccine boy and nurse

Mar 31, 2021 by Brian Orelli, PhD

Pfizer and BioNTech's COVID-19 Vaccine Produces 100% Protection in Kids

The companies plan to apply for emergency use authorization in adolescents in the coming weeks.

Doctor male patient

Mar 30, 2021 by Brian Orelli, PhD

Here's Why Wave Life Sciences Crashed Today

No one ever said drug development was easy.

Can_GoodRx_Bounce_Back_From_Its_Pandemic_Slowdown[1]

Mar 28, 2021 by Brian Orelli, PhD and Keith Speights

Can GoodRx Bounce Back From Its Pandemic Slowdown?

Some of the drug discounter's growth is out of the company's hands.

Is_Veeva’s_Public_Benefit_Corp._Status_a_Blessing_or_a_Curse[1]

Mar 25, 2021 by Brian Orelli, PhD and Keith Speights

Is Veeva's Public Benefit Corp. Status a Blessing or a Curse?

The company is no longer singularly beholden to shareholders.

Should_Investors_Be_Worried_About_DermTech_s_Decline_From_Its_52-Week_Highs[1]

Mar 25, 2021 by Brian Orelli, PhD and Keith Speights

Should Investors Be Worried About DermTech's Decline From Its 52-Week Highs?

Think long-term with this dermatology company.

Is_Amgen’s_Acquisition_of_Five_Prime_a_Good_Move_for_the_Big_Biotech[1]

Mar 25, 2021 by Brian Orelli, PhD and Keith Speights

Is Amgen's Acquisition of Five Prime a Good Move for the Big Biotech?

The drugmaker needs as much potential revenue as it can acquire at a reasonable price.

Is_Oscar_Heath’s_IPO_Flop_a_Buying_Opportunity[1]

Mar 25, 2021 by Brian Orelli, PhD and Keith Speights

Is Oscar Heath's IPO Flop a Buying Opportunity?

The valuation metric assigned to the company will determine whether the health insurer is really on sale.

Sarepta_Therapeutics’_Long-Term_Potential_Is_in_Flux[1]

Mar 25, 2021 by Brian Orelli, PhD and Keith Speights

Sarepta Therapeutics' Long-Term Potential Is in Flux

While revenue continues to grow, the biotech's future hinges on its gene therapy SRP-9001.

Where_Does_Fulgent_Genetics_Go_From_Here[1]

Mar 25, 2021 by Brian Orelli, PhD and Keith Speights

Where Does Fulgent Genetics Go From Here?

COVID-19 testing has been a huge opportunity for the genetic testing company, but how long will it last?

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services